je.st
news
International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
2014-12-10 14:45:00| Merck.com - Research & Development News
Dateline City: SAN ANTONIO Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need SAN ANTONIO--(BUSINESS WIRE)--The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care. Language: English Contact: International Breast Cancer Study GroupLaura Cava Northrop, 617-632-3973press@ibcsg.orgorBreast International GroupCecilia Waldvogel, +41 79 478-0238cecilia.waldvogel@BIGagainstbc.orgorMerckClaire Mulhearn, 908-236-1118claire.mulhearn@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: international
group
study
opening
Category:Biotechnology and Pharmaceuticals